Explore /
Poster
/ Bromodomain and extra-terminal (BET) inhibitor INCB057643 (LIMBER-103) in patients (pts) with relapsed or refractory myelofibrosis (R/R MF) and other advanced myeloid neoplasms: A phase 1 study.

Bromodomain and extra-terminal (BET) inhibitor INCB057643 (LIMBER-103) in patients (pts) with relapsed or refractory myelofibrosis (R/R MF) and other advanced myeloid neoplasms: A phase 1 study.

Authors

Justin M. Watts

Sylvester Cancer Center, University of Miami, Miami, FL

Justin M. Watts , Anthony Hunter , Alessandra Iurlo , Blanca Xicoy , Francesca Palandri , Brandi Reeves , Alessandro M. Vannucchi , Prithviraj Bose , Rosa Ayala Diaz , Anna B. Halpern , Xuejun Chen , Francis Seguy , Feng Zhou , Fred Zheng , Pankit Vachhani

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Track

Hematologic Malignancies

Sub Track

Myeloproliferative Neoplasms (MPN) and Mast Cell Disorders

Clinical Trial Registration Number

NCT04279847

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 7069)

DOI

10.1200/JCO.2023.41.16_suppl.7069

Abstract #

7069

Poster Bd #

199

Abstract Disclosures

Similar Posters

Poster

2024 ASCO Annual Meeting

$Bromodomain and extra-terminal (BET) inhibitor INCB057643 in patients with relapsed or refractory myelofibrosis (MF) and other advanced myeloid neoplasms: A phase 1 study.$